Literature DB >> 24337727

Characterization of cognitive dysfunction in Sjögren's syndrome patients.

Lynn C Epstein1, Gina Masse, Jerold S Harmatz, Tammy M Scott, Athena S Papas, David J Greenblatt.   

Abstract

Sjögren's syndrome is an autoimmune disorder primarily affecting women, with decreased saliva and tear production as the principal characteristic. Cognitive, neurological, and psychiatric disorders also are associated with Sjögren's. The present study addressed the hypothesis that patients with Sjögren's syndrome differ significantly from matched controls in the prevalence and impact of a number of neuropsychiatric abnormalities. Sjögren's patients and controls (n = 37 per group) underwent medical and psychiatric evaluation, demographic assessments, quality of life and symptom evaluation, and extensive testing of cognitive function and memory. Patients and controls were closely matched for age, gender distribution, verbal IQ, marital status, educational level, employment status, and current/past medical or psychiatric history. On most subjective self-ratings, Sjögren's patients reported greater fatigue, impaired physical functioning, feeling depressed, and autonomic symptomatology compared to controls. Impaired memory was described mainly as loss of thought continuity in the midst of a task or activity. However, the majority of objective measures of cognition, psychomotor function, and memory showed minimal differences between groups. Sjögren's patients rate themselves as impaired on multiple ratings of emotional, cognitive, and physical function, but objective measures of cognition reveal fewer substantive differences between patients and matched controls. Sjögren's patients perceive deteriorated physical function over time, but they achieve a level of functioning comparable to controls despite the burden of their illness.

Entities:  

Mesh:

Year:  2013        PMID: 24337727     DOI: 10.1007/s10067-013-2453-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  43 in total

Review 1.  CNS involvement in primary Sjögren's syndrome: prevalence, clinical aspects, diagnostic assessment and therapeutic approach.

Authors:  M Govoni; M Padovan; N Rizzo; F Trotta
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  CNS Sjögren's syndrome: an underrecognized and underappreciated neuropsychiatric disorder.

Authors:  P D Cox; R E Hales
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1999       Impact factor: 2.198

Review 3.  Clinical manifestations and early diagnosis of Sjögren syndrome.

Authors:  Stuart S Kassan; Haralampos M Moutsopoulos
Journal:  Arch Intern Med       Date:  2004-06-28

4.  Pharmacokinetics and pharmacodynamics of diphenhydramine 25 mg in young and elderly volunteers.

Authors:  J M Scavone; D J Greenblatt; J S Harmatz; N Engelhardt; R I Shader
Journal:  J Clin Pharmacol       Date:  1998-07       Impact factor: 3.126

5.  Oral pilocarpine for symptomatic relief of dry mouth and dry eyes in patients with Sjögrens syndrome.

Authors:  A S Papas; M M Fernandez; R A Castano; S C Gallagher; M Trivedi; R C Shrotriya
Journal:  Adv Exp Med Biol       Date:  1998       Impact factor: 2.622

Review 6.  Treatment of primary Sjögren syndrome: a systematic review.

Authors:  Manuel Ramos-Casals; Athanasios G Tzioufas; John H Stone; Antoni Sisó; Xavier Bosch
Journal:  JAMA       Date:  2010-07-28       Impact factor: 56.272

Review 7.  Sjögren's syndrome.

Authors:  Robert I Fox
Journal:  Lancet       Date:  2005 Jul 23-29       Impact factor: 79.321

8.  Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients.

Authors:  Sophie Delalande; Jérôme de Seze; Anne-Laure Fauchais; Eric Hachulla; Tanya Stojkovic; Didier Ferriby; Sylvain Dubucquoi; Jean-Pierre Pruvo; Patrick Vermersch; Pierre-Yves Hatron
Journal:  Medicine (Baltimore)       Date:  2004-09       Impact factor: 1.889

9.  Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo.

Authors:  D J Greenblatt; J S Harmatz; C Dorsey; R I Shader
Journal:  Clin Pharmacol Ther       Date:  1988-09       Impact factor: 6.875

10.  Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study.

Authors:  Charles DeBattista; Karl Doghramji; Matthew A Menza; Murray H Rosenthal; Ronald R Fieve
Journal:  J Clin Psychiatry       Date:  2003-09       Impact factor: 4.384

View more
  7 in total

1.  Vision-specific and cancer-specific quality of life in ocular graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Authors:  Yinglin Liao; Wenxin Zhao; Jing Yang; Shaowen Wu; Ling Jin; Fen Huang; Lingyi Liang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-08-27       Impact factor: 3.535

2.  Hospitalization Risks for Neurological Disorders in Primary Sjögren's Syndrome Patients.

Authors:  Radjiv Goulabchand; Audrey Gabelle; Xavier Ayrignac; Nicolas Malafaye; Pierre Labauge; Danièle Noël; Jacques Morel; Camille Roubille; Lucie Barateau; Philippe Guilpain; Thibault Mura
Journal:  J Clin Med       Date:  2022-04-01       Impact factor: 4.241

3.  Cognition, depression, fatigue, and quality of life in primary Sjögren's syndrome: correlations.

Authors:  Belgin Koçer; Mehmet Engin Tezcan; Hale Zeynep Batur; Şeminur Haznedaroğlu; Berna Göker; Ceyla İrkeç; Rümeysa Çetinkaya
Journal:  Brain Behav       Date:  2016-10-13       Impact factor: 2.708

Review 4.  Impact of pain on cognitive functions in primary Sjögren syndrome with small fiber neuropathy: 10 cases and a literature review.

Authors:  Sandrine Indart; Jacques Hugon; Pierre Jean Guillausseau; Alice Gilbert; Julien Dumurgier; Claire Paquet; Damien Sène
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

5.  Cognitive impairment in patients with Neuro-Sjögren.

Authors:  Tabea Seeliger; Lena Jacobsen; Merle Hendel; Lena Bönig; Nils K Kristian Prenzler; Thea Thiele; Diana Ernst; Torsten Witte; Martin Stangel; Bruno Kopp; Thomas Skripuletz
Journal:  Ann Clin Transl Neurol       Date:  2020-07-06       Impact factor: 4.511

6.  Increased Risk of Sjögren's Syndrome in Patients with Obsessive-Compulsive Disorder: A Nationwide Population-Based Cohort Study.

Authors:  Yi-Jung Chang; Jui-Cheng Tseng; Pui-Ying Leong; Yu-Hsun Wang; James Cheng-Chung Wei
Journal:  Int J Environ Res Public Health       Date:  2021-06-01       Impact factor: 3.390

7.  Epidemiology of neurological manifestations in Sjögren's syndrome: data from the French ASSESS Cohort.

Authors:  Guillermo Carvajal Alegria; Dewi Guellec; Xavier Mariette; Jacques-Eric Gottenberg; Emmanuelle Dernis; Jean-Jacques Dubost; Anne-Priscille Trouvin; Eric Hachulla; Claire Larroche; Veronique Le Guern; Divi Cornec; Valérie Devauchelle-Pensec; Alain Saraux
Journal:  RMD Open       Date:  2016-04-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.